PLAUR and neoplasm: For uPAR-RPT, [177Lu]Lu-DOTA-AE105 substantially decreased the number of metastatic lesions in disseminated metastatic PC tumour-bearing mice compared with that in control mice; moreover, 65% of the mice did not develop disseminated metastatic lesions at 65 days after the initial administration.203